arrow
A

Antoni Gostyński

Maastricht University Medical Centre
H指数:15
被引数:808

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay

度普利尤单抗与特拉斯库单抗在特应性皮炎中的倾向评分调整比较:来自BioDay的数据

2026-04-130
OAAI
Multi-omics profiling of chronic immune-mediated skin diseases: SKINERGY protocol and strategic evaluation
2026-02-060
OAAI
Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry

特应性皮炎中的药物生存率:生物制剂与JAK抑制剂的BioDay登记研究比较

2025-12-010
OAAI
Response to Bissonnette et al “Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD)”

对Bissonnette et al. “Dupilumab治疗可恢复特应性皮炎患者(成人及青少年)的皮损和非皮损皮肤屏障功能,且与filaggrin基因型无关:BALISTAD开放标签、健康对照匹配、4期临床研究的结果”的回应

2025-08-290
PRE
A proposal for a new pathogenesis-guided classification for inherited epidermal differentiation disorders

一种基于发病机制指导的遗传性表皮分化障碍的新分类方案

2025-08-015
PRE
Syndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy

综合征性表皮分化障碍:基于病生理机制的新分类与治疗方向

2025-08-019
OAAI
Palmoplantar epidermal differentiation disorders: a new classification toward pathogenesis-based therapy

掌跖表皮分化障碍:一种新的基于发病机制的分类向疗法

2025-08-0115
OA
Nonsyndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy

非综合征性表皮分化障碍:基于与疾病相关基因的新分类和命名法,以实现靶向治疗

2025-08-015
OAAI
Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results

特应性皮炎患者使用生物制剂和JAK抑制剂治疗时的感染风险:BioDay研究数据

2025-04-030
OAAI
Exploring shared clinical features and successful therapeutic interventions in CARD14-associated papulosquamous eruption
2024-11-200
OA
Molecular analysis of inherited disorders of cornification in polish patients show novel variants and functional data and provokes questions on the significance of secondary findings
2024-11-050
OAAI